Health CareMedical Equipment and Services
  • Price (USD)278.28
  • Today's Change1.62 / 0.58%
  • Shares traded1.12m
  • 1 Year change+1.95%
  • Beta0.9381
Data delayed at least 15 minutes, as of Mar 29 2023 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Stryker Corporation (Stryker) is a medical technology company. The Company offers products and services in Medical and Surgical, Neurotechnology, Orthopedics and Spine that help improve patient and healthcare outcomes. The Company operates through two segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. Its products are sold in over 75 countries through Company-owned subsidiaries and branches, as well as through third-party dealers and distributors. Its products include surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment and intensive care disposable products; clinical communication and workflow solutions; neurosurgical and neurovascular devices; implants used in joint replacement and trauma surgeries; Mako Robotic-Arm Assisted technology; spinal devices; as well as other products used in a variety of medical specialties. Its geographical segments include United States and International.

  • Revenue in USD (TTM)18.45bn
  • Net income in USD2.36bn
  • Incorporated1946
  • Employees51.00k
  • Location
    Stryker Corp2825 Airview BlvdKALAMAZOO 49002United StatesUSA
  • Phone+1 (269) 389-2600
  • Fax+1 (269) 385-1062
  • Websitehttps://www.stryker.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SYK:NYQ since
Cerus Endovascular IncAnnounced30 Sep 202230 Sep 2022Announced35.43%--
Data delayed at least 15 minutes, as of Mar 29 2023 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Insulet Corporation1.31bn4.60m21.76bn2.60k5,608.5345.66320.9416.670.05580.055818.636.850.60711.547.12502,038.500.2140.57250.24820.653761.7264.860.35240.93462.652.380.74640.0018.7922.99-72.62--15.29--
Align Technology, Inc.3.73bn361.57m23.46bn23.17k66.596.5748.136.284.604.6047.6246.610.62823.874.25161,218.906.0819.648.9928.8570.5272.429.6825.931.08--0.000.00-5.5120.44-53.172.758.33--
West Pharmaceutical Services Inc.2.89bn580.20m25.10bn10.70k44.159.3336.918.707.667.7338.1136.230.83314.415.79269,803.8016.1514.8719.2417.7339.3637.0619.3817.142.90--0.072212.011.9512.54-12.1420.0616.826.61
Zimmer Biomet Holdings Inc6.94bn290.20m26.62bn18.00k91.902.2021.873.841.381.1033.0257.510.31180.88934.98385,550.001.310.9761.511.1170.9071.
Resmed Inc3.76bn809.47m31.37bn8.16k38.828.3632.578.345.505.5025.5825.530.65962.066.04461,185.7014.1913.1916.1015.5156.7157.3321.5118.671.8222.560.325140.4511.9311.6064.2617.8916.904.94
GE HealthCare Technologies Inc18.34bn1.90bn35.97bn50.00k18.953.8513.931.964.184.2240.4320.58------366,820.00--------39.14--10.63--0.85732.480.4624--4.30---14.85------
DexCom, Inc.2.91bn341.20m44.04bn7.50k142.3020.6588.5915.130.80090.80096.845.520.56363.054.74387,973.306.616.488.797.8565.1966.5811.7311.041.831,012.750.48780.0018.8432.2857.3143.7940.77--
Edwards Lifesciences Corp5.38bn1.52bn49.48bn17.30k33.488.5529.789.192.442.448.629.550.6411.358.79311,121.4018.1216.3220.6519.0479.9676.3228.2824.432.17--0.09310.002.869.401.2511.648.57--
Becton Dickinson and Co18.74bn1.49bn68.84bn77.00k46.932.7118.433.675.185.3065.3489.720.35193.128.40243,350.702.962.213.422.5144.7845.788.416.550.59956.320.392586.56-1.369.312.058.456.00--
Boston Scientific Corporation12.68bn642.00m70.54bn45.00k110.044.0039.615.560.4460.4468.8112.260.3922.266.77281,822.202.162.752.473.2869.0069.035.527.
Intuitive Surgical, Inc.6.22bn1.32bn87.83bn12.12k68.677.9550.5714.123.653.6517.1931.550.46912.747.21513,382.8010.1412.8611.2814.2967.4468.3021.6127.143.77--
Medtronic PLC30.77bn4.06bn105.20bn95.00k25.992.0415.483.423.043.0423.0638.670.3312.075.43323,915.804.405.085.045.7266.7268.4613.2915.451.3923.050.352762.615.211.3043.974.581.767.94
Stryker Corp18.45bn2.36bn105.79bn51.00k45.226.3631.525.736.176.1748.2743.880.5161.865.60361,745.106.596.437.777.5963.1464.8712.7812.790.9964--0.439944.457.848.1918.254.94-0.336710.77
Data as of Mar 29 2023. Currency figures normalised to Stryker Corp's reporting currency: US Dollar USD

Institutional shareholders

37.81%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202228.83m7.61%
Greenleaf Asset Management, Inc.as of 21 Mar 202321.05m5.56%
Wellington Management Co. LLPas of 31 Dec 202217.03m4.50%
BlackRock Fund Advisorsas of 31 Dec 202215.80m4.17%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 202214.96m3.95%
SSgA Funds Management, Inc.as of 31 Dec 202214.12m3.73%
Capital Research & Management Co. (Global Investors)as of 31 Dec 202214.08m3.72%
Fundsmith LLPas of 31 Dec 20227.25m1.91%
Geode Capital Management LLCas of 31 Dec 20225.84m1.54%
Franklin Advisers, Inc.as of 31 Dec 20224.26m1.13%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.